Trial · NCT00579111
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
NCT00579111, Phase 1, Phase 2, Terminated, Baylor College of Medicine; results first posted 2012-08-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB). Trials, record NCT00579111. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00579111
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
- NCT number
- NCT00579111
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Baylor College of Medicine
- Conditions
Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders, Hematologic Diseases
- Interventions
- Campath, Busulfan, Fludarabine, Hematopoietic stem cell infusion, FK-506
- First posted
- 2007-12-21
- Last updated
- 2016-05-04
- Results first posted
- 2012-08-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Successful Donor Engraftment | 100 days | Each patient will be classified as a success or failure. A success will be defined as engraftment of at least 35% of cells 100 days after transplant. |
| Secondary | Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity | 100 days |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With Successful Donor Engraftment | 100 days | participants | NUMBER | |
| SECONDARY | Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity | 100 days | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Successful Donor Engraftment | HLA-identical Sibling Transplant | 2 | participants | ||
| Number of Patients With Successful Donor Engraftment | Unrelated Matched or Single Antigen Mismatched Transplant | 1 | participants | ||
| Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity | HLA-identical Sibling Transplant | 1 | participants | ||
| Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity | Unrelated Matched or Single Antigen Mismatched Transplant | 0 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | HLA-identical Sibling Transplant | 3 | |
| Overall Study | STARTED | Unrelated Matched or Single Antigen Mismatched Transplant | 1 | |
| Overall Study | COMPLETED | HLA-identical Sibling Transplant | 1 | |
| Overall Study | COMPLETED | Unrelated Matched or Single Antigen Mismatched Transplant | 0 | |
| Overall Study | NOT COMPLETED | HLA-identical Sibling Transplant | 2 | |
| Overall Study | NOT COMPLETED | Unrelated Matched or Single Antigen Mismatched Transplant | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Blood/Bone Marrow - Other: Engraftment Failure | Blood and lymphatic system disorders | HLA-identical Sibling Transplant | 1 | 3 | 1 |
| serious | Blood/Bone Marrow - Other: Engraftment Failure | Blood and lymphatic system disorders | Unrelated Matched or Single Antigen Mismatched Transplant | 0 | 1 | 0 |
| serious | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e | Infections and infestations | HLA-identical Sibling Transplant | 1 | 3 | 2 |
| serious | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e | Infections and infestations | Unrelated Matched or Single Antigen Mismatched Transplant | 0 | 1 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | HLA-identical Sibling Transplant | ||
| Total, all-cause mortality | Unrelated Matched or Single Antigen Mismatched Transplant | ||
| Total, other adverse events | HLA-identical Sibling Transplant | 0 | 3 |
| Total, other adverse events | Unrelated Matched or Single Antigen Mismatched Transplant | 0 | 1 |
| Total, serious adverse events | HLA-identical Sibling Transplant | 2 | 3 |
| Total, serious adverse events | Unrelated Matched or Single Antigen Mismatched Transplant | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| HLA-identical Sibling Transplant vs Unrelated Matched or Single Antigen Mismatched Transplant: Number of Patients With Successful Donor Engraftment | Trial comparisons |
| HLA-identical Sibling Transplant vs Unrelated Matched or Single Antigen Mismatched Transplant: Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity | Trial comparisons |
| HLA-identical Sibling Transplant vs Unrelated Matched or Single Antigen Mismatched Transplant: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00579111
GET https://conductscience.org/api/trials/v1/NCT00579111/registered